P005 Overcoming Secondary Loss of Response to Infliximab in Patients With Ulcerative Colitis With the Use of Mesenchymal Stromal Cells
نویسندگان
چکیده
منابع مشابه
Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab.
Pyoderma gangrenosum is an extraintestinal manifestation of inflammatory bowel disease that can be therapeutically troublesome. We comment on the case of a patient with clinically inactive ulcerative colitis who progressively developed necrotic lesions on both tibial aspects of his legs, which corresponded both clinically and histologically to pyoderma gangrenosum. Treatment with steroids and a...
متن کاملmodern surgical techniques in treatment of patients with cleft lip & cleft palate
چکیده ندارد.
15 صفحه اولMucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.
BACKGROUND AND AIMS Infliximab is an effective treatment for ulcerative colitis with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-tumour necrosis factor alpha (anti-TNFalpha) is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in ulcerative colitis. ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Gastroenterology
سال: 2020
ISSN: 0002-9270,1572-0241
DOI: 10.14309/01.ajg.0000722816.53201.fa